glp-1 agonist drug interactions Comparing Ozempic, Wegovy and Other Drugs Glucagon-Like Peptide-1 Receptor Agonists in

If not, it would require further review

Papakonstantinou I, Tsioufis K, Katsi V (2024) Spotlight on the Mechanism of Action of Semaglutide

Another novel glucose-lowering agent is tirzepatide which has a dual mechanism of action: a GLP-1 and a glucose-dependent insulinotropic polypeptide (GIP) co-agonist

10.1007/s10787-022-00956-6 Inflammopharmacology 4 Aviles-OlmosI.DicksonJ.KefalopoulouZ.DjamshidianA.EllP.SoderlundT.et al (2013)

The most common side effects of tirzepatide are gastrointestinal: Nausea: Reported by 12-33% of participants depending on dose (most common early in treatment) Diarrhea: 12-21% of participants Constipation: 6-11% of participants Vomiting: 5-13% of participants Decreased appetite: Expected therapeutic effect but can be uncomfortable These side effects are typically most intense during the first few weeks at each new dose level and tend to improve as the body adjusts

Patients with type 2 diabetes mellitus have higher risk for acute pancreatitis compared with those without diabetes